康泰医学(300869) - 2025 Q2 - 季度财报

Important Notice, Table of Contents, and Definitions This section provides an important notice, the report's table of contents, and definitions of key terms and entities Important Notice The Board of Directors, senior management, and accounting personnel guarantee the report's accuracy and completeness, advising investors to review risk factors - The company's Board of Directors, senior management, and accounting personnel guarantee the truthfulness, accuracy, and completeness of the semi-annual report content[3] - Risks and countermeasures in the company's operations are described in "Section III Management Discussion and Analysis" under "X. Risks Faced by the Company and Countermeasures"[3] - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for this half-year period[4] Table of Contents The report's eight main chapters cover company profile, management discussion, corporate governance, significant matters, share changes, bond information, and financial reports - The report contains eight main chapters, covering company profile, management discussion and analysis, corporate governance, significant matters, share changes and shareholder information, bond-related information, and financial reports[6] List of Documents for Reference Reference documents, including signed financial statements and original announcements, are available at the company's securities affairs department office - Reference documents include signed and sealed financial statements, original publicly disclosed company documents, and original semi-annual report and abstract texts signed by the legal representative and stamped with the company seal[8][9][10] - All reference documents are located at the company's securities affairs department office[11] Definitions This report defines regulatory bodies, the company and its key subsidiaries, and specifies the reporting period and prior year's corresponding period - The report clearly defines regulatory bodies such as the China Securities Regulatory Commission (CSRC), Shenzhen Stock Exchange (SZSE), and Securities Regulatory Bureau[12] - The company and its major subsidiaries, including Contec USA, Contec Germany, Contec India, Wolong Technology, Xinjia Medical, Changsha Yixin, and Contec Yichao, are clearly defined[12] - The reporting period is from January 1, 2025, to June 30, 2025, and the prior year's corresponding period is from January 1, 2024, to June 30, 2024[12] Company Profile and Key Financial Indicators This section details the company's basic information, contact details, and presents key accounting data and financial indicators for the reporting period Company Profile Contec Medical Systems (Qinhuangdao) Co., Ltd., stock code 300869, is listed on the Shenzhen Stock Exchange, with Hu Kun as its legal representative Company Basic Information | Indicator | Content | | :--- | :--- | | Stock Abbreviation | Contec Medical | | Stock Code | 300869 | | Stock Exchange | Shenzhen Stock Exchange | | Company Chinese Name | 康泰医学系统（秦皇岛）股份有限公司 | | Company English Name | Contec Medical Systems Co.,Ltd | | Legal Representative | Hu Kun | Contact Persons and Information The company's Board Secretary and Securities Affairs Representative share the same contact address, phone, fax, and email Contact Information | Position | Name | Contact Address | Phone | Fax | Email | | :--- | :--- | :--- | :--- | :--- | :--- | | Board Secretary | Zheng Min | No. 112 Qinhuang West Street, Economic and Technological Development Zone, Qinhuangdao City | 0335-8015593 | 0335-8015422 | contec_sec@hotmail.com | | Securities Affairs Representative | Lv Yang | No. 112 Qinhuang West Street, Economic and Technological Development Zone, Qinhuangdao City | 0335-8015593 | 0335-8015422 | contec_sec@hotmail.com | Other Information The company's registered address, website, email, and information disclosure locations remained unchanged during the reporting period - The company's contact information, information disclosure and storage locations, and registration status remained unchanged during the reporting period; specific details can be found in the 2024 annual report[16][17][18] Key Accounting Data and Financial Indicators In H1 2025, revenue increased by 2.72% to RMB 218 million, net profit attributable to shareholders surged by 107.39%, and operating cash flow grew by 86.78% 2025 Semi-Annual Key Accounting Data and Financial Indicators | Indicator | Current Reporting Period (RMB) | Prior Year Corresponding Period (RMB) | YoY Change in Current Reporting Period | | :--- | :--- | :--- | :--- | | Operating Revenue | 217,549,459.94 | 211,789,804.52 | 2.72% | | Net Profit Attributable to Shareholders of Listed Company | 16,937,573.17 | 8,167,120.79 | 107.39% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Gains and Losses) | 12,453,493.18 | -3,853,547.41 | 423.17% | | Net Cash Flow from Operating Activities | 25,895,451.16 | 13,864,467.64 | 86.78% | | Basic Earnings Per Share (RMB/share) | 0.04 | 0.02 | 100.00% | | Diluted Earnings Per Share (RMB/share) | 0.04 | 0.02 | 100.00% | | Weighted Average Return on Net Assets | 0.92% | 0.40% | 0.52% | | Indicator | End of Current Reporting Period (RMB) | End of Prior Year (RMB) | Change from End of Prior Year | | :--- | :--- | :--- | :--- | | Total Assets | 2,768,851,265.62 | 2,725,517,187.03 | 1.59% | | Net Assets Attributable to Shareholders of Listed Company | 1,774,028,298.37 | 1,857,415,749.92 | -4.49% | Differences in Accounting Data under Domestic and Overseas Accounting Standards The company reports no differences in net profit or net assets between international/overseas and Chinese accounting standards for the reporting period - The company reports no differences in net profit and net assets between financial reports disclosed under international accounting standards and those under Chinese accounting standards for the reporting period[20] - The company reports no differences in net profit and net assets between financial reports disclosed under overseas accounting standards and those under Chinese accounting standards for the reporting period[21] Non-Recurring Gains and Losses and Amounts Non-recurring gains and losses totaled RMB 4.48 million, primarily from government grants, fair value changes, and other non-operating income/expenses 2025 Semi-Annual Non-Recurring Gains and Losses and Amounts | Item | Amount (RMB) | | :--- | :--- | | Government grants included in current profit/loss (excluding those with continuous impact) | 1,516,924.40 | | Gains and losses from changes in fair value of financial assets and liabilities held by non-financial enterprises, and gains and losses from disposal of financial assets and liabilities | 3,602,204.41 | | Other non-operating income and expenses apart from the above items | 172,577.09 | | Loss on disposal of non-current assets | -16,317.68 | | Less: Income tax impact | 791,308.23 | | Total | 4,484,079.99 | - The company has no other profit and loss items that meet the definition of non-recurring gains and losses, nor does it classify non-recurring gains and losses as recurring gains and losses[24] Management Discussion and Analysis This section provides an in-depth analysis of the company's business operations, financial performance, and risk factors during the reporting period Principal Business Activities During the Reporting Period The company primarily engages in R&D, production, and sales of medical devices, serving hospital, home, and other markets, with strong industry growth - The company's main business is the research and development, production, and sales of medical diagnostic and monitoring equipment, belonging to the medical device industry[31] - During the reporting period, the company's main business revenue accounted for 98.95%, with no significant changes in its main business or principal products[31] Industry Overview The medical device industry, driven by aging populations and chronic diseases, shows strong demand and global expansion, with China's market rapidly innovating - The medical device industry exhibits strong demand rigidity and is not significantly cyclical[26] - The global medical device market continues to expand, with the Asia-Pacific region experiencing the fastest growth, and China solidifying its position as the world's second-largest medical device market[27] - In H1 2025, the National Medical Products Administration (NMPA) approved 45 innovative medical devices, an 87% increase year-on-year, with policies continuously encouraging R&D innovation and industrial upgrading[28][29] - The company has become a modern high-tech enterprise integrating R&D, production, and sales, with a complete product system, mastery of core technologies, and some products achieving industry-leading technical performance, selling to over 140 countries and regions worldwide[30] Main Business The company's main business involves R&D, production, and sales of medical diagnostic and monitoring equipment, categorized into hospital, home, and other product lines - The company's product system includes hospital-use, home-use, and other categories, covering various products such as blood oxygen, ECG, ultrasound, monitoring, blood pressure, and analysis and testing[31][32] - The company primarily adopts a hybrid production model combining make-to-order, assemble-to-order, and make-to-stock[51] - Sales models primarily involve distribution overseas, while domestic sales combine distribution and direct sales, supplemented by consignment sales and covering mainstream e-commerce platforms both domestically and internationally[52] - The company's profitability primarily stems from the difference between sales and after-sales service revenue and the costs and expenses of medical diagnostic and monitoring equipment and related accessories[53] - Performance growth drivers include an aging population and the trend towards home-based healthcare, high R&D investment, successful new product launches (such as zirconia blocks, blood glucose meters, in-vitro diagnostic reagents), and a globalized layout with localized strategies[54] Main Products The company offers a diverse product portfolio across hospital, home, and other categories, including ultrasound, ECG, monitoring, and blood oxygen devices - Hospital-use products include ultrasound Doppler fetal monitors, laptop ultrasound diagnostic equipment, color Doppler ultrasound diagnostic systems, ECG machines, dynamic ECG recorders, exercise stress ECG testing systems, ECG workstations, portable ECG devices, large/portable self-service physical examination equipment, portable/multi-parameter/plug-in patient monitors, sleep apnea monitors, handheld/desktop spirometers, semi-automatic/fully automatic biochemical analyzers, blood cell analyzers, specific protein analyzers, fluorescence immunoassay analyzers, urine analyzers, arteriosclerosis detectors, medical infrared thermometers, infusion pumps, and syringe pumps[33][34][35][36][37][38] - Home-use products include finger-clip/wrist/desktop/handheld/wearable pulse oximeters, pulse oximetry modules, ambulatory blood pressure monitors, arm-type electronic blood pressure monitors, medical compressor/mesh nebulizers, medical/home oxygen concentrators, single-level positive airway pressure therapy devices, ultrasound Doppler fetal heart rate monitors, electric breast pumps, blood glucose meters, blood glucose and uric acid meters, blood lipid meters, blood glucose test strips, H. pylori test strips, early pregnancy test strips, uric acid test strips, cholesterol test strips, blood lipid test cards, low-frequency electronic massagers, infrared lamps, insect bite itch relievers, sleep posture trainers, and infant movement sensors[39][40][41][42][43][44] - Other products include digital EEG topographic mappers, ambulatory EEG recorders, multi-parameter simulators, pulse oximeter simulators, non-invasive blood pressure simulators, zirconia blocks for all-ceramic dentures, electromyography evoked potential instruments, portable phlegm aspirators, stethoscopes, hearing aids, pneumatic external counterpulsation devices, dynamic vital signs monitors, end-tidal carbon dioxide monitors, medical endoscope camera systems, medical endoscope LED cold light sources, anesthetic video laryngoscopes, and disposable anesthetic laryngoscope blades[45][46][47][48] Medical Device Registration Status The company actively pursues domestic and international medical device registrations and certifications, with several products in review or already approved - For domestic registration, products such as color Doppler ultrasound diagnostic systems, patient monitors, arm-type electronic blood pressure monitors, multi-parameter vital signs monitors, ultrasound bone densitometers, and portable ECG devices are in the technical review stage[55] - For domestic registration, medical endoscope LED cold light sources and medical endoscope camera systems have obtained Class II medical device registration certificates[55] - For EU CE certification, color Doppler ultrasound diagnostic systems, infusion pumps, and insect bite itch relievers are in the technical review or technical document preparation stage[56] - For FDA registration, color Doppler ultrasound diagnostic systems, spirometers, and pulse oximeters are in the data preparation or standard testing stage[58] - For Canadian registration, color Doppler ultrasound diagnostic systems are in the data preparation stage, and pocket fetal Dopplers have obtained registration certificates[59] - For Indian registration, ECG machines, patient monitors, electronic blood pressure monitors, spirometers, fetal Dopplers, infusion pumps, and nebulizers have obtained registration certificates[77][78] - As of the end of the reporting period, the company and its subsidiaries have obtained 68 valid medical device registration (filing) qualifications, including 1 Class III medical device registration certificate, 62 Class II medical device registration certificates, and 5 Class I medical device filings; they have also obtained 57 market access permits in major countries/regions worldwide[99] Analysis of Core Competencies The company's core strengths lie in R&D innovation, product diversification, scaled production, quality control, marketing network, and comprehensive sales services - The company's core competencies are reflected in six aspects: R&D innovation, product diversification, scaled production, product quality, marketing network, and sales service system[79] R&D Innovation Advantage The company maintains high R&D investment, achieving technological breakthroughs and new product launches, evidenced by numerous patents and software copyrights - The company's R&D investment was RMB 46.48 million, driving technological innovation and integrated product innovation with high-level investment[80] - The company achieved technological breakthroughs in respiratory products, developing pulse oxygen portable oxygen concentrators, new lightweight and stylish 3-liter and silent and efficient smart 5-liter medical oxygen concentrators, and high-end home and portable ventilators[81] - In blood pressure products, multiple cuff-free arm-type electronic blood pressure monitors were launched, and 360° smart pressurization technology for arm-cuff blood pressure monitors was developed[81] - For hospital-use products, the basic algorithms for new monitoring products were optimized, EEG (electroencephalogram) monitoring technology and NMT (neuromuscular transmission monitoring) technology were independently developed, and key technological breakthroughs were achieved in medical endoscopes, including video laryngoscopes and 4K image processing systems[82] - In the treatment field, the company independently developed the first Class III medical device – the pneumatic external counterpulsation device[84] - During the reporting period, the company added 61 domestic patents (3 invention patents, 22 utility model patents, 36 design patents) and 117 software copyrights[85][88] Product Diversification Advantage The company's extensive product portfolio across hospital, home, and other categories enables diverse solutions and customized offerings for clients - The company possesses three major product systems: hospital-use, home-use, and other categories, covering various products such as blood oxygen, ECG, ultrasound, monitoring, blood pressure, and analysis and testing, as well as digital medical health services[93] - The company can quickly combine various product functions to meet customer demands for integrated medical device functionalities, which helps deepen cooperation with customers[94] Scaled Production Advantage With a complete industrial chain and localized key components, the company demonstrates strong rapid response and large-scale production capabilities - The company possesses a complete industrial chain covering mold injection, chip mounting, software burning, and product assembly, achieving domestic substitution for key raw materials and core components in its main products[95] - The company has strong capabilities for rapid order response and large-scale production and delivery, with some product supply capabilities leading the industry[95] - The "Contec Industrial Park Construction Project" (Development Zone) has completed its main structure and is in the interior and exterior decoration and supporting facilities construction phase; the "Contec Medical Medical Device Industrial Park Project" (Beidaihe) has completed its main structure and decoration, and is in the supporting facilities construction phase[96] Product Quality Advantage The company prioritizes product quality through a comprehensive management system, achieving multiple certifications and market access permits globally - The company has established a comprehensive quality management system covering R&D, procurement, production, sales, and after-sales service, and has passed ISO9001 and ISO13485 quality management system certifications[97] - The company has been awarded the Hebei Provincial Government Quality Award multiple times, including again in 2020[98] - As of the end of the reporting period, the company and its subsidiaries have obtained 68 valid medical device registration (filing) qualifications, and 57 market access permits in major countries/regions worldwide[99] - During the reporting period, 2 new domestic medical device registration certificates and 5 new Indian medical device registration certificates were obtained[100][101] Marketing Network Advantage The company operates a global marketing network, expanding into new markets and enhancing e-commerce partnerships, supported by overseas warehouses - The company has established a global marketing network combining distribution and direct sales, as well as B2B and B2C, with products sold to over 140 countries and regions including North America, Europe, Southeast Asia, Latin America, and the Middle East[102] - During the reporting period, the company intensified its market development efforts in Africa, Europe, Southeast Asia, and South America, and plans to establish a wholly-owned subsidiary in Dubai, UAE[103] - Overseas warehouse construction continues to advance, with stable operations in the US, India, and Germany, and upcoming operations in Brazil, Mexico, and Dubai[103] - In the domestic market, the company deepened cooperation with JD Health, Ali Health platforms, and Tmall Supermarket's health category, primarily promoting new home-use test strip products such as blood glucose, early pregnancy, and H. pylori tests[104][105] Sales Service System Advantage The company provides a comprehensive pre-sale, in-sale, and after-sale service system, ensuring customer satisfaction and equipment operational reliability - The company has established a comprehensive pre-sale, in-sale, and after-sale service system, including product consultation, demand analysis, delivery of qualified products, installation and commissioning, and repair and maintenance[106] - The company has a dedicated technical department for after-sales service, staffed with a professional technical service team[106] Analysis of Main Business In H1 2025, revenue slightly increased, while operating costs significantly decreased, leading to substantial profit growth, with improved gross margins for home and hospital products Major Financial Data Year-on-Year Changes | Indicator | Current Reporting Period (RMB) | Prior Year Corresponding Period (RMB) | YoY Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 217,549,459.94 | 211,789,804.52 | 2.72% | | | Operating Cost | 86,114,414.21 | 106,962,931.79 | -19.49% | | | Selling Expenses | 42,412,618.74 | 36,429,656.30 | 16.42% | | | Administrative Expenses | 17,112,193.37 | 17,826,736.72 | -4.01% | | | Financial Expenses | -4,628,575.27 | -8,832,295.07 | 47.59% | Primarily due to a decrease in exchange gains compared to the prior year | | Income Tax Expenses | 1,555,167.49 | 337,211.53 | 361.18% | Primarily due to an increase in profit in the current reporting period | | R&D Expenses | 46,481,133.59 | 56,055,044.05 | -17.08% | | | Net Cash Flow from Operating Activities | 25,895,451.16 | 13,864,467.64 | 86.78% | Primarily due to an increase in operating revenue and corresponding increase in collections during the reporting period | | Net Cash Flow from Investing Activities | 13,133,916.12 | 405,915,579.61 | -96.76% | Primarily due to a decrease in revolving purchases of wealth management products compared to the prior year | | Net Cash Flow from Financing Activities | 15,922,261.90 | -385,884,145.94 | 104.13% | Primarily due to an increase in short-term borrowings during the reporting period | | Net Increase in Cash and Cash Equivalents | 53,159,505.17 | 36,795,354.13 | 44.47% | Primarily due to the combined effect of the above three reasons | | Other Income | 5,523,541.59 | 3,984,036.36 | 38.64% | Primarily due to an increase in government grants received compared to the prior year | | Investment Income | 849,480.10 | 11,098,894.68 | -92.35% | Primarily due to a decrease in wealth management income compared to the prior year | | Fair Value Change Income | 2,752,724.31 | 1,548,798.82 | 77.73% | Primarily due to an increase in fair value change income from wealth management products in the current reporting period | | Credit Impairment Losses | 107,054.65 | -1,418,946.35 | -107.54% | Primarily due to an increase in bad debt provision reversals for accounts receivable in the current reporting period | | Asset Impairment Losses | -16,022,591.50 | -6,129,554.46 | 161.40% | Primarily due to an increase in inventory depreciation provision based on impairment indicators in the current reporting period | Product or Service Accounting for Over 10% of Revenue | Product or Service | Operating Revenue (RMB) | Operating Cost (RMB) | Gross Margin | YoY Change in Operating Revenue | YoY Change in Operating Cost | YoY Change in Gross Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Home-use Products | 89,210,773.96 | 47,173,263.28 | 47.12% | 7.62% | -16.71% | 48.79% | | Hospital-use Products | 103,420,331.97 | 29,416,600.86 | 71.56% | -6.85% | -29.95% | 15.09% | - The company's profit composition or sources of profit did not undergo significant changes during the reporting period[108] Analysis of Non-Principal Business Non-principal business activities, including investment income and fair value changes, positively impacted profit, but asset impairment, mainly inventory write-downs, had a significant negative effect Impact of Non-Principal Business on Total Profit | Item | Amount (RMB) | Percentage of Total Profit | Explanation of Formation | Sustainability | | :--- | :--- | :--- | :--- | :--- | | Investment Income | 849,480.10 | 4.59% | | No | | Fair Value Change Income | 2,752,724.31 | 14.89% | | No | | Asset Impairment | -16,022,591.50 | -86.64% | Primarily due to inventory depreciation provision in the current reporting period | No | | Non-Operating Income | 495,178.41 | 2.68% | | No | | Non-Operating Expenses | 338,919.00 | 1.83% | | No | Analysis of Assets and Liabilities Total assets slightly increased, with significant growth in investment properties and short-term borrowings, while fixed assets decreased, and certain assets are pledged Significant Changes in Asset Composition | Item | Amount at End of Current Reporting Period (RMB) | Percentage of Total Assets | Amount at End of Prior Year (RMB) | Percentage of Total Assets | Change in Proportion | | :--- | :--- | :--- | :--- | :--- | :--- | | Cash and Bank Balances | 737,467,276.65 | 26.63% | 684,307,771.48 | 25.11% | 1.52% | | Accounts Receivable | 39,604,096.77 | 1.43% | 45,998,781.84 | 1.69% | -0.26% | | Inventories | 277,275,030.66 | 10.01% | 272,322,956.49 | 9.99% | 0.02% | | Investment Properties | 59,621,815.82 | 2.15% | 8,265,877.77 | 0.30% | 1.85% | | Fixed Assets | 198,343,646.65 | 7.16% | 259,352,784.07 | 9.52% | -2.36% | | Construction in Progress | 89,318,209.48 | 3.23% | 72,847,298.84 | 2.67% | 0.56% | | Right-of-Use Assets | 3,019,096.67 | 0.11% | 3,867,651.58 | 0.14% | -0.03% | | Short-Term Borrowings | 165,000,000.00 | 5.96% | 60,000,000.00 | 2.20% | 3.76% | | Contract Liabilities | 34,517,114.42 | 1.25% | 32,036,930.34 | 1.18% | 0.07% | | Lease Liabilities | 1,642,150.31 | 0.06% | 1,834,700.40 | 0.07% | -0.01% | - The company reports no major overseas assets during the reporting period[114] Assets and Liabilities Measured at Fair Value | Item | Beginning Balance (RMB) | Fair Value Change Gain/Loss for Current Period (RMB) | Amount Purchased in Current Period (RMB) | Amount Sold in Current Period (RMB) | Ending Balance (RMB) | | :--- | :--- | :--- | :--- | :--- | :--- | | Trading Financial Assets (excluding derivative financial assets) | 171,588,083.19 | 1,203,925.49 | 700,000,000.00 | 230,000,000.00 | 642,752,724.31 | | Total | 171,588,083.19 | 1,203,925.49 | 700,000,000.00 | 230,000,000.00 | 642,752,724.31 | Restricted Asset Rights as of the End of the Reporting Period | Item | Book Balance (RMB) | Book Value (RMB) | Type of Restriction | Restriction Status | | :--- | :--- | :--- | :--- | :--- | | Other Non-Current Assets | 10,000,000.00 | 10,000,000.00 | Pledge | Short-term loan pledge | | Other Non-Current Assets Due Within One Year | 110,000,000.00 | 110,000,000.00 | Pledge | Short-term loan pledge | | Fixed Assets | 90,577,868.60 | 33,801,576.82 | Mortgage | Loan repaid, unreleased mortgage | | Investment Properties | 12,086,498.07 | 6,047,752.63 | Mortgage | Loan repaid, unreleased mortgage | | Intangible Assets | 5,748,937.62 | 3,655,167.88 | Mortgage | Loan repaid, unreleased mortgage | | Total | 228,413,304.29 | 163,504,497.33 | | | Analysis of Investment Status Total investment decreased due to reduced wealth management product purchases, with significant fair value financial assets and ongoing convertible bond projects - The investment amount for the reporting period was RMB 2.493 billion, a 4.74% decrease compared to the prior year, mainly due to reduced revolving purchases of wealth management products[117] - The company had no significant equity investments or ongoing significant non-equity investments during the reporting period[118] Financial Assets Measured at Fair Value | Asset Category | Initial Investment Cost (RMB) | Fair Value Change Gain/Loss for Current Period (RMB) | Amount Purchased in Reporting Period (RMB) | Amount Sold in Reporting Period (RMB) | Ending Balance (RMB) | Source of Funds | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Other | 171,588,083.19 | 1,203,925.49 | 700,000,000.00 | 230,000,000.00 | 642,752,724.31 | Own funds, raised funds | | Total | 171,588,083.19 | 1,203,925.49 | 700,000,000.00 | 230,000,000.00 | 642,752,724.31 | | Overall Utilization of Raised Funds | Fundraising Year | Fundraising Method | Total Raised Funds (RMB 10,000) | Net Raised Funds (RMB 10,000) | Total Accumulated Used Raised Funds (RMB 10,000) | Percentage of Raised Funds Used at End of Reporting Period | | :--- | :--- | :--- | :--- | :--- | :--- | | 2020 | Initial Public Offering of A-shares | 41,656 | 37,400.76 | 40,010.07 | 106.98% | | 2022 | Issuance of Convertible Corporate Bonds to Unspecified Investors | 70,000 | 68,827.03 | 11,309.52 | 16.43% | | Total | | 111,656 | 106,227.79 | 51,319.59 | 48.31% | - The 2020 A-share IPO fundraising project was completed in 2023 and fully utilized by June 30, 2025; the 2022 convertible bond fundraising project is currently under construction[121] - As of June 30, 2025, the company's remaining raised funds amounted to RMB 632.4318 million, of which RMB 625 million was used for cash management[121] - The company changed the use of convertible bond raised funds, reallocating unused funds from the "Contec Industrial Park Construction Project" to the "Contec Industrial Park Construction Project" (Development Zone) and the "Contec Medical Medical Device Industrial Park Project" (Beidaihe) to adapt to market demand changes and new product R&D expansion[126][132] - The company chose not to recognize right-of-use assets and lease liabilities for short-term leases of buildings[349] Entrusted Wealth Management, Derivative Investments, and Entrusted Loans The company engaged in entrusted wealth management with both own funds and raised funds, totaling RMB 640 million in outstanding balance, with no derivative or entrusted loan activities Overview of Entrusted Wealth Management During the Reporting Period | Specific Type | Source of Entrusted Wealth Management Funds | Amount of Entrusted Wealth Management (RMB 10,000) | Outstanding Balance (RMB 10,000) | | :--- | :--- | :--- | :--- | | Brokerage Wealth Management Products | Own Funds | 6,000 | 3,000 | | Brokerage Wealth Management Products | Raised Funds | 64,000 | 61,000 | | Total | | 70,000 | 64,000 | - The company reports no derivative investments or entrusted loans during the reporting period[135] Significant Asset and Equity Sales The company did not engage in any significant asset or equity sales during the reporting period - The company reports no significant asset sales during the reporting period[136] - The company reports no significant equity sales during the reporting period[137] Analysis of Major Holding and Participating Companies Key subsidiaries include CONTEC MEDICAL SYSTEMS USA INC. and Changsha Contec Medical Core Biotechnology Co., Ltd., with one subsidiary deregistered during the period Major Subsidiaries and Participating Companies with Over 10% Impact on Company's Net Profit | Company Name | Company Type | Main Business | Registered Capital (RMB) | Total Assets (RMB) | Net Assets (RMB) | Operating Revenue (RMB) | Operating Profit (RMB) | Net Profit (RMB) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | CONTEC MEDICAL SYSTEMS USA INC. | Subsidiary | Sales of medical instruments and health products | 17,374,521.88 | 63,827,799.07 | 49,275,758.78 | 21,254,988.39 | 8,763,842.53 | 6,090,870.55 | | Changsha Contec Medical Core Biotechnology Co., Ltd. | Subsidiary | Technology development, manufacturing, and sales of bio-based materials and medical devices; production and sales of Class I medical devices; sales of Class II medical devices; manufacturing and sales of special ceramic products, etc. | 50,000,000.00 | 16,816,018.47 | 11,542,873.89 | 3,967,848.63 | -4,262,230.12 | -4,172,417.19 | - During the reporting period, Qinhuangdao Wolong Technology Co., Ltd. was deregistered, which had no impact on the overall production, operations, or performance[138] Structured Entities Controlled by the Company The company did not control any structured entities during the reporting period - The company reports no structured entities controlled during the reporting period[139] Risks Faced by the Company and Countermeasures The company addresses market competition, R&D, quality, internal management, exchange rate, trade policy, and talent retention risks through strategic initiatives - The company faces market competition risks and will respond by continuously investing in R&D, differentiating products, and strengthening sales channels[139] - The company faces R&D innovation risks and will maintain high investment, enhance product performance and technical levels, and strengthen its marketing network and after-sales service[140] - The company faces quality control risks and will actively monitor market policies and regulatory requirements, adhere to quality management system construction, and ensure product quality[141] - The company faces internal management risks, requiring management to formulate correct development strategies based on market environment changes and improve management capabilities and levels[142] - The company faces exchange rate risks and will control them through financial measures such as adjusting the proportion of domestic and international sales and foreign exchange hedging[143] - The company faces international trade policy change risks and will closely monitor the international trade environment, enhance customer loyalty, and expand into emerging markets[144] - The company faces talent loss risks and needs to offer competitive compensation and incentive mechanisms to maintain a stable talent pool[146] Registration Form for Research, Communication, Interview, and Other Activities During the Reporting Period On May 16, 2025, the company held an online investor briefing to discuss performance, operations, R&D, and corporate governance - On May 16, 2025, the company conducted an online exchange via the Panorama Network "Investor Relations Interactive Platform," hosting investors who participated in the 2024 annual online performance briefing[147] - Key discussion topics included the company's performance, operational status, R&D plans, and corporate governance[147] Formulation and Implementation of Market Value Management System and Valuation Enhancement Plan The company adopted a Market Value Management System on March 5, 2025, to regulate market value activities, but has not disclosed a valuation enhancement plan - The company has formulated a "Market Value Management System," which was reviewed and approved at the 17th meeting of the Fourth Board of Directors on March 5, 2025[148] - The company has not disclosed a valuation enhancement plan[148] "Dual Improvement in Quality and Returns" Action Plan Implementation Status The company has not disclosed an announcement regarding the "Dual Improvement in Quality and Returns" action plan - The company has not disclosed an announcement regarding the "Dual Improvement in Quality and Returns" action plan[149] Corporate Governance, Environment, and Society This section covers changes in the company's governance structure, profit distribution plans, environmental disclosures, and social responsibility initiatives Changes in Directors, Supervisors, and Senior Management During the reporting period, Director Zheng Min resigned due to work relocation, and Gao Ruibin was elected as an employee representative director Changes in Directors, Supervisors, and Senior Management | Name | Position | Type | Date | Reason | | :--- | :--- | :--- | :--- | :--- | | Zheng Min | Director | Resignation | May 20, 2025 | Work relocation | | Gao Ruibin | Employee Representative Director | Election | May 20, 2025 | Work relocation | | Jia Baofeng | Supervisor | Resignation | May 20, 2025 | Work relocation | | Zhang Qiang | Supervisor | Resignation | May 20, 2025 | Work relocation | - Former Director Zheng Min resigned from her directorship due to internal work adjustments[151] - Due to supervisory board reform, former supervisory board members resigned, and Gao Ruibin was elected as an employee representative director[152][153][154] Profit Distribution and Capital Reserve Conversion to Share Capital for the Reporting Period The company plans no cash dividends, bonus shares, or capital reserve conversions to share capital for this half-year period - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the half-year period[155] Implementation of Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures in place during the reporting period - The company reports no equity incentive plans, employee stock ownership plans, or other employee incentive measures and their implementation during the reporting period[156] Environmental Information Disclosure The listed company and its major subsidiaries are not included in the list of enterprises required to disclose environmental information by law - The listed company and its major subsidiaries are not included in the list of enterprises required to disclose environmental information by law[157] Social Responsibility The company, as a national medical device enterprise, operates legally, protects stakeholders' rights, and actively participates in social welfare initiatives - The company is committed to providing more and higher-quality medical device products for the public, promoting the advancement of China's medical and health undertakings and improving people's health levels[157] - During the reporting period, the company operated legally and compliantly, effectively protected the interests of investors, especially public shareholders, safeguarded the legitimate rights and interests of employees, treated suppliers and customers with integrity, and actively participated in social welfare undertakings, fulfilling its corporate social responsibility[157] Significant Matters This section addresses commitments, related party transactions, litigation, and other significant events during the reporting period Commitments Fulfilled and Overdue Unfulfilled by Controlling Shareholder, Shareholders, Related Parties, Acquirers, and the Company During and as of the End of the Reporting Period The company reports no fulfilled or overdue unfulfilled commitments by its controlling shareholder, shareholders, related parties, acquirers, or the company - The company reports no commitments fulfilled during the reporting period or overdue unfulfilled as of the end of the reporting period by its actual controller, shareholders, related parties, acquirers, or the company[159] Non-Operating Funds Occupied by Controlling Shareholder and Other Related Parties from the Listed Company The company reports no non-operating funds occupied by its controlling shareholder or other related parties from the listed company during the reporting period - The company reports no non-operating funds occupied by its controlling shareholder or other related parties from the listed company during the reporting period[160] Irregular External Guarantees The company reports no irregular external guarantees during the reporting period - The company reports no irregular external guarantees during the reporting period[161] Appointment and Dismissal of Accounting Firms The company's semi-annual financial report was not audited - The company's semi-annual report was not audited[162] Explanations by the Board of Directors, Supervisory Board, and Audit Committee on the "Non-Standard Audit Report" for the Current Reporting Period The company had no non-standard audit report for the current period, thus no explanation from the Board, Supervisory Board, or Audit Committee is required - The company reports no non-standard audit report for the current reporting period[163] Explanations by the Board of Directors on the "Non-Standard Audit Report" for the Previous Year The company had no non-standard audit report for the previous year, thus no explanation from the Board is required - The company reports no non-standard audit report for the previous year[163] Bankruptcy and Reorganization Matters The company did not experience any bankruptcy or reorganization matters during the reporting period - The company reports no bankruptcy or reorganization matters during the reporting period[163] Litigation Matters A patent lawsuit with Beijing Choice Electronic Technology Co., Ltd. was settled for USD 1 million, with no adverse impact on the company's operations - The patent litigation case between the company and Beijing Choice Electronic Technology Co., Ltd. in the United States was settled on December 10, 2024[164] - The company and Contec USA paid a settlement of USD 1,000,000.00 to Beijing Choice, and received a "Stipulated Permanent Injunction and Order of Dismissal" from the U.S. District Court for the Northern District of Illinois on January 9, 2025[165] - The patents involved in this case do not concern the company's core patents, technologies, or products, and the controlling shareholder and actual controller, Mr. Hu Kun, has paid the settlement compensation, so this ruling will not adversely affect the company's production and operations[165] - The company reports no other litigation matters during the reporting period[166] Penalties and Rectification Status The company reports no penalties or rectification situations during the reporting period - The company reports no penalties or rectification situations during the reporting period[167] Integrity Status of the Company, its Controlling Shareholder, and Actual Controller The company, its controlling shareholder, and actual controller maintained integrity during the reporting period, with no unfulfilled obligations or overdue debts - The company, its controlling shareholder, and actual controller maintained integrity during the reporting period, with no unfulfilled obligations determined by effective legal documents or significant overdue debts[168] Significant Related Party Transactions The company reports no significant related party transactions, including daily operations, asset/equity sales, joint investments, or debt during the reporting period - The company reports no related party transactions related to daily operations during the reporting period[169] - The company reports no related party transactions involving asset or equity acquisition/disposal during the reporting period[170] - The company reports no related party transactions involving joint external investment during the reporting period[171] - The company reports no related party creditor-debtor transactions during the reporting period[172] - The company has no deposits, loans, credit lines, or other financial business with related financial companies, nor do its controlled financial companies have such dealings with related parties[173][174] - The company reports no other significant related party transactions during the reporting period[175] Significant Contracts and Their Performance The company leased out property, but the resulting profit/loss was not significant, and no other major contracts or guarantees were reported - In May 2025, the company leased out property belonging to the Shenzhen Intelligent Medical Equipment Industry Research Institute, but the resulting profit or loss did not exceed 10% of the company's total profit for the reporting period[178] - The company reports no trusteeship, contracting, significant guarantees, disclosable significant daily operating contracts, or other significant contracts during the reporting period[176][177][179][180][181] Explanation of Other Significant Matters All other significant matters required by the Securities Law and information disclosure regulations were disclosed as temporary reports - During the reporting period, all significant matters required by the "Securities Law" and "Measures for the Administration of Information Disclosure by Listed Companies" were disclosed as temporary reports on the Shenzhen Stock Exchange website and other information disclosure media meeting the conditions specified by the China Securities Regulatory Commission[182] Significant Matters of Company Subsidiaries The company reports no significant matters concerning its subsidiaries during the reporting period - The company reports no significant matters concerning its subsidiaries during the reporting period[183] Share Changes and Shareholder Information This section details changes in share capital, securities issuance, shareholder numbers, and holdings of directors, supervisors, and senior management Share Change Status Restricted shares held by directors and senior management decreased by 1,791,750 shares, increasing unrestricted shares, with no material impact on key financial metrics - At the beginning of the reporting period, the statutory transferable quota for shares held by the company's directors and senior management at the end of the previous year was calculated at 25%, resulting in a decrease of 1,791,750 restricted shares and a corresponding increase in unrestricted shares[186][187] - The share changes had no significant impact on basic earnings per share, diluted earnings per share, or net assets per common share attributable to the company's common shareholders for the most recent year and period[187] Securities Issuance and Listing Status The company reports no securities issuance or listing activities during the reporting period - The company reports no securities issuance or listing activities during the reporting period[188] Number of Shareholders and Shareholding Status As of the reporting period end, the company had 31,078 common shareholders, with controlling shareholder Hu Kun holding 43.85% of shares - The total number of common shareholders at the end of the reporting period was 31,078[189] Shareholding of Shareholders Holding 5% or More or Top 10 Shareholders | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held at End of Reporting Period (shares) | Change in Shareholding During Reporting Period | Number of Restricted Shares Held (shares) | Number of Unrestricted Shares Held (shares) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Hu Kun | Domestic Natural Person | 43.85% | 176,189,283 | -11,999,969 | 141,141,939 | 35,047,344 | | Wang Guili | Domestic Natural Person | 11.73% | 47,126,226 | 0 | 0 | 47,126,226 | | Hong Kong Securities Clearing Company Limited | Overseas Legal Person | 0.93% | 3,737,624 | 1,907,821 | 0 | 3,737,624 | | Fu Chunyuan | Domestic Natural Person | 0.62% | 2,476,772 | 0 | 1,857,579 | 619,193 | | Yang Zhishan | Domestic Natural Person | 0.54% | 2,157,138 | 0 | 1,617,853 | 539,285 | | Kou Guozhi | Domestic Natural Person | 0.46% | 1,846,977 | 0 | 1,385,233 | 461,744 | | Golden Eagle Fund - GF Securities Co., Ltd. - Golden Eagle Preferred No. 152 Single Asset Management Plan | Other | 0.32% | 1,288,000 | 0 | 0 | 1,288,000 | | Gao Ruibin | Domestic Natural Person | 0.31% | 1,230,902 | 0 | 923,176 | 307,726 | | Yang Zhen | Domestic Natural Person | 0.30% | 1,212,100 | -250,300 | 0 | 1,212,100 | | Penghua Fund Management Co., Ltd. - Social Security Fund 1804 Portfolio | Other | 0.30% | 1,204,508 | 0 | 0 | 1,204,508 | Changes in Restricted Shares | Shareholder Name | Restricted Shares at Beginning of Period (shares) | Restricted Shares Released in Current Period (shares) | Restricted Shares at End of Period (shares) | Reason for Restriction | | :--- | :--- | :--- | :--- | :--- | | Hu Kun | 141,141,939 | 0.00 | 141,141,939 | Restricted shares for senior management | | Yang Zhishan | 2,157,103 | 539,250.00 | 1,617,853 | Restricted shares for senior management | | Fu Chunyuan | 1,857,579 | 0.00 | 1,857,579 | Restricted shares for senior management | | Kou Guozhi | 1,842,733 | 457,500.00 | 1,385,233 | Restricted shares for senior management | | Gao Ruibin | 1,223,176 | 300,000.00 | 923,176 | Restricted shares for senior management | | Xu Yunlong | 886,089 | 217,500.00 | 668,589 | Restricted shares for senior management | | Liu Zhenhong | 633,207 | 157,500.00 | 475,707 | Restricted shares for senior management | | Zheng Min | 491,907 | 120,000.00 | 371,907 | Restricted shares for senior management | | Total | 150,233,733 | 1,791,750.00 | 148,441,983 | | Changes in Shareholdings of Directors, Supervisors, and Senior Management Chairman Hu Kun's shareholding decreased by 11,999,969 shares, while other directors, supervisors, and senior management had no changes Changes in Shareholdings of Directors, Supervisors, and Senior Management | Name | Position | Employment Status | Shares Held at Beginning of Period (shares) | Shares Reduced in Current Period (shares) | Shares Held at End of Period (shares) | | :--- | :--- | :--- | :--- | :--- | :--- | | Hu Kun | Chairman | Current | 188,189,252 | 11,999,969 | 176,189,283 | | Total | | | 188,189,252 | 11,999,969 | 176,189,283 | Changes in Controlling Shareholder or Actual Controller The company's controlling shareholder and actual controller remained unchanged during the reporting period - The company's controlling shareholder remained unchanged during the reporting period[193] - The company's actual controller remained unchanged during the reporting period[193] Preferred Share Information The company had no preferred shares during the reporting period - The company had no preferred shares during the reporting period[194] Bond-Related Information This section provides details on the company's convertible bonds, including issuance, conversion, and credit ratings, and confirms no other bond types Corporate Bonds The company reports no corporate bonds during the reporting period - The company reports no corporate bonds during the reporting period[196] Company Bonds The company reports no company bonds during the reporting period - The company reports no company bonds during the reporting period[197] Debt Financing Instruments for Non-Financial Enterprises The company reports no debt financing instruments for non-financial enterprises during the reporting period - The company reports no debt financing instruments for non-financial enterprises during the reporting period[198] Convertible Corporate Bonds The company issued RMB 700 million in convertible bonds in 2022, with 99.97% remaining unconverted, maintaining a stable credit rating - On July 1, 2022, the company issued 7,000,000 convertible corporate bonds, raising a total of RMB 700,000,000.00, with the bond abbreviation "Contec Convertible Bond" and bond code "123151"[199] - At the end of the period, there were 12,659 convertible bondholders, and the company's convertible bonds have no guarantor[200] Cumulative Conversion Status | Convertible Corporate Bond Name | Total Issued (shares) | Total Issued Amount (RMB) | Cumulative Converted Amount (RMB) | Cumulative Converted Shares (shares) | Percentage of Converted Shares to Total Issued Shares Before Conversion Start Date | Unconverted Amount (RMB) | Percentage of Unconverted Amount to Total Issued Amount | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Contec Medical Systems (Qinhuangdao) Co., Ltd. Convertible Corporate Bonds Issued to Unspecified Investors | 7,000,000 | 700,000,000.00 | 174,600.00 | 6,177 | 0.00% | 699,824,400.00 | 99.97% | - The conversion price has been adjusted multiple times, with the latest conversion price at the end of this reporting period being RMB 27.55/share[203][204] - As of the end of this reporting period, the company's asset-liability ratio was 35.93%, an increase of 4.08 percentage points from the beginning of the period; China Lianhe Credit Rating Co., Ltd. maintained the company's long-term corporate credit rating at A+ and the "Contec Convertible Bond" credit rating at A+, with a stable outlook[205] - The company's production and operations are stable, cash flow is abundant, and financial income and expenditure are sound; the main source of funds for repaying convertible bond principal and interest in future years will be cash flow generated from operating activities[206] [Consolidated Statement Scope Loss Exceeding 10% of Net Assets at Year-End](index=84&type=section&id=%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%90%88%E5%B9%B6%E6%8A%A5%E8%A1%A8%E8%8C%83%E5%9B%B4%E4%BA%8F%E6%8D%9F%E8%B6%85%E8%BF%87%E4%B8%8A%E5%B9%B4%E6%9C%